NasdaqGM:HRMYPharmaceuticals
Assessing Harmony Biosciences (HRMY) Valuation After CFO’s Complete Exit From Direct Equity Ownership
Multiple open market share sales by Harmony Biosciences Holdings (HRMY) Chief Financial Officer Sandip Kapadia, culminating in a full exit from direct equity ownership, have put the company’s insider activity firmly in focus for investors.
See our latest analysis for Harmony Biosciences Holdings.
The recent insider sales have landed against a mixed performance backdrop, with the share price at US$37.48 and a 90 day share price return of 19.55% contrasting with a 1 year total shareholder...